AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Haemonetics Corporation (HAE)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

63.40

-0.26 (-0.41%)

At close: Feb 20, 2025, 3:59 PM

63.45

0.08%

After-hours: Feb 20, 2025, 06:30 PM EST

undefined% (undefined)

Bid	61.46
Market Cap	3.19B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	2.54
PE Ratio (ttm)	24.96
Forward PE	n/a
Analyst	Buy

Ask	72
Volume	453,854
Avg. Volume (20D)	790,871
Open	64.09
Previous Close	63.66
Day's Range	63.09 - 64.36
52-Week Range	58.80 - 97.97
Beta	undefined

About HAE

Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their d...

[Show more]

Industry Medical - Instruments & Supplies

Sector Healthcare

IPO Date May 10, 1991

Employees 3,657

Stock Exchange NYSE

Ticker Symbol HAE

Website https://www.haemonetics.com

Full Company Profile

Analyst Forecast

According to 9 analyst ratings, the average rating for HAE stock is "Buy." The 12-month stock price forecast is $108, which is an increase of 70.35% from the latest price.

Buy 77.78%

Hold 22.22%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Haemonetics Corporation is scheduled to release its earnings on May 8, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 weeks ago

-11.58%

Haemonetics shares are trading lower after the com... Unlock content with Pro Subscription

3 months ago

+10.71%

Haemonetics shares are trading higher after the company reported better-than-expected Q2 financial results.

News

4 days ago · seekingalpha.com

Astria Therapeutics: A High-Conviction Bet On HAE

Astria Therapeutics' strong cash position and efficient spending provide a financial runway through mid-2027, reducing dilution risk and supporting pivotal trials for navenibart and STAR-0310. Navenib...

2 weeks ago · zacks.com

HAE Q3 Earnings In Line, '25 Sales View Cut, Stock Up in Aftermarket

Haemonetics' third-quarter fiscal 2025 results reflect the positive effects of the company's long-range plan with meaningful earnings growth and margin expansion.

2 weeks ago · seekingalpha.com

Haemonetics Corporation (HAE) Q3 2025 Earnings Call Transcript

Haemonetics Corporation (NYSE:HAE ) Q3 2025 Earnings Conference Call February 6, 2025 8:30 AM ET Company Participants Olga Guyette - Vice President, Investor Relations and Treasury Christopher Simon -...

2 weeks ago · zacks.com

Haemonetics (HAE) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Haemonetics (HAE) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall S...

2 weeks ago · zacks.com

Haemonetics (HAE) Q3 Earnings Meet Estimates

Haemonetics (HAE) came out with quarterly earnings of $1.19 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $1.04 per share a year ago.

4 weeks ago · zacks.com

Here's Why Haemonetics (HAE) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

1 month ago · zacks.com

HAE or ABT: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Products stocks are likely familiar with Haemonetics (HAE) and Abbott (ABT). But which of these two companies is the best option for those looking for undervalued sto...

1 month ago · zacks.com

Completion of Whole Blood Assets Sale to GVS Likely to Boost HAE Stock

Haemonetics completes the sale of whole blood assets to GVS, S.p.A.

1 month ago · zacks.com

Why Haemonetics (HAE) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

1 month ago · zacks.com

HAE vs. ABT: Which Stock Is the Better Value Option?

Investors interested in stocks from the Medical - Products sector have probably already heard of Haemonetics (HAE) and Abbott (ABT). But which of these two stocks offers value investors a better bang ...

Load More News